Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 8Terminated 2Recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 197Lymphoid 17Other solid neoplasm 11Gynecologic 9Thoracic 7Tumor-Agnostic 6Genitourinary 3Dermatologic 3Other hematologic neoplasm 2CNS 2Sarcoma 1Head & Neck 1Breast 1

Conditions

Thyroid Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Glioma 1Endometrial Neoplasms 1Desmoid Tumors 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenomatous Polyposis Coli 1

Interventions

Temozolomide 78Magnetic Resonance Spectroscopy 69Specimen Handling 45Radiotherapy 42Bevacizumab 28Radiosurgery 27Cyclophosphamide 27pembrolizumab 20Radiation 20Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 14Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11Surgical Procedures, Operative 9trametinib 8dinutuximab 8abemaciclib 8Ipilimumab 8Fluorodeoxyglucose F18 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Oxaliplatin × CNS × Clear all
NCT05355701 2026-05-14

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

NCT05919264 2026-05-12

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Parabilis Medicines, Inc.

Phase 1/2 Recruiting
595 enrolled
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡